EUVIMEDEUVIMED entdecken
Crossref

Comparative analysis of curative efficacy and prognostic factors across treatment modalities for early-stage hepatocellular carcinoma (BCLC 0/A)

Wen Zheng, Ping Lv, Qiang Zhu, Qing-Lin Zhang, Gang-Gang Yin, Wei-Gang Chen

World Journal of Gastrointestinal Oncology · 15.07.2026 · 18 (7)

DOI: 10.4251/wjgo.119136 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Gastrointestinal Oncology, online erschienen am 15.07.2026. Verfasst von Wen Zheng und 5 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND While the prognostic impact of radiofrequency ablation (RFA) vs liver resection (LR) remains controversial for Barcelona Clinic Liver Cancer (BCLC) stage 0/A hepatocellular carcinoma (HCC). AIM To comparatively analyze prognostic outcomes across therapeutic approaches. METHODS We conducted a multicenter retrospective analysis of treatment-naïve HCC patients meeting BCLC stage 0/A criteria at the First Affiliated Hospital of Shihezi University and Shandong Provincial Hospital between January 2012 and December 2022, stratifying patients into three therapeutic cohorts: LR monotherapy (LR; n = 30), RFA alone (RFA; n = 40), and combined therapy (LR plus adjuvant treatment; n = 32), with primary endpoints of five-year overall survival (OS), progression-free survival (PFS), and median survival time analyzed using Kaplan-Meier (K-M) methodology. RESULTS A total of 102 patients with HCC were included, and they were followed up until December 31, 2023. The follow-up rate was 100%. Treatment modalities significantly impacted five-year OS (P = 0.03). Cox regression confirmed both LR [hazard ratio (HR) = 0.297; 95% confidence interval (CI): 0.104-0.848; P = 0.02] and combination therapy (HR = 0.331; 95%CI: 0.118-0.931; P = 0.04) significantly reduced mortality risk versus RFA. Furthermore, K-M analysis demonstrated significant differences in OS among the three treatment modalities (RFA, LR, and combined treatment; log-rank test, P = 0.02), and the LR group exhibited significantly improved 5-year OS compared to the RFA group (P = 0.047). Similarly, significant differences in PFS were observed among the three treatment modalities (log-rank test, P = 0.009), and both the LR group (P = 0.049) and combined therapy group (P = 0.033) exhibited significantly longer PFS compared to the RFA group. CONCLUSION We recommend LR as the first-line therapeutic option for early-stage HCC, while advocating active pursuit of combination therapy regimens for high-risk early-stage HCC patients to obtain comparable survival outcomes with LR alone.

Zitieren

APA

Zheng, W., Lv, P., Zhu, Q., Zhang, Q., Yin, G., & Chen, W. (2026). Comparative analysis of curative efficacy and prognostic factors across treatment modalities for early-stage hepatocellular carcinoma (BCLC 0/A). World Journal of Gastrointestinal Oncology, 18(7). https://doi.org/10.4251/wjgo.119136

Vancouver

Zheng W, Lv P, Zhu Q, Zhang Q, Yin G, Chen W. Comparative analysis of curative efficacy and prognostic factors across treatment modalities for early-stage hepatocellular carcinoma (BCLC 0/A). World Journal of Gastrointestinal Oncology. 2026;18(7). doi:10.4251/wjgo.119136

BibTeX
@article{Zheng2026,
  author = {Zheng, Wen and Lv, Ping and Zhu, Qiang and Zhang, Qing-Lin and Yin, Gang-Gang and Chen, Wei-Gang},
  title = {Comparative analysis of curative efficacy and prognostic factors across treatment modalities for early-stage hepatocellular carcinoma (BCLC 0/A)},
  journal = {World Journal of Gastrointestinal Oncology},
  year = {2026},
  volume = {18},
  number = {7},
  doi = {10.4251/wjgo.119136}
}
Kostenlos starten →